# Lack of effect of N-acetylcysteine on the release of oxygen radicals from neutrophils and alveolar macrophages

E. Drost\*, S. Lannan\*, M.M.E. Bridgeman\*\*\*, D. Brown\*\*, C. Selby\*, K. Donaldson\*\*, W. MacNee\*

Lack of effect of N-acetylcysteine on the release of oxygen radicals from neutrophils and alveolar macrophages. E. Drost, S. Lannan, M.M.E. Bridgeman, D. Brown, C. Selby, K. Donaldson, W. MacNee.

ABSTRACT: N-acetylcysteine (NAC) is rapidly de-acetylated *in vivo* to cysteine (CYSH), a precursor of glutathione (GSH) which is an antioxidant in cells and body fluids.

We investigated the effect of oral administration of N-acetyl cysteine for 5 days on the spontaneous and stimulated generation of hydrogen peroxide  $(H_2O_2)$  and superoxide anion  $(O_2^{-})$  from human and rat phagocytic leucocytes. Alveolar macrophages (AM) were obtained by bronchoalveolar lavage (BAL) in control rats and rats given NAC in their drinking water. Neutrophils (PMNL) were harvested from whole blood in normal nonsmoking volunteers before and after NAC was given by mouth.

The stimulated release of  $H_2O_2$  and  $O_2^-$  from both rat AM and human PMN was not changed by administration of NAC. However, a small but significant increase was observed in both the spontaneous generation of  $O_2^-$  from rat AM and the spontaneous generation of  $H_2O_2$  from human PMNL. Administration of NAC significantly increased cysteine levels in human plasma and rat BAL, but the levels in human PMNL and rat AM after NAC did not differ from control levels. GSH levels were not altered significantly by NAC. Eur Respir J., 1991, 4, 723–729.

Phagocytic cells, alveolar macrophages and neutrophils, are present in increased numbers in the lungs of cigarette smokers [1-3] and patients with inflammatory lung diseases [4-6]. Stimulation of these inflammatory cells results in the release of proteolytic enzymes and an increase in the respiratory burst, causing the release of reactive oxygen intermediates [7–9]. Inappropriate or excessive release of these oxygen radicals may cause damage to the lung tissue, either directly, by peroxidation of membrane lipids and proteins, or indirectly by inactivating protease inhibitors, thus favouring proteolysis. The balance between the release of oxidants, and their inactivation by antioxidants could therefore be critical to the prevention of lung damage during the inflammatory response to bacteria and irritant inhalants such as cigarette smoke. Agents capable of reducing the release of oxidants, or inactivating them once released could therefore have a therapeutic value.

Excess reactive oxygen intermediates can be efficiently removed by the actions of superoxide dismutase on the superoxide anion  $(O_2^{-})$ , and by catalase and peroxidases on hydrogen peroxide  $(H_2O_2)$ . Moreover, reducing the concentrations of  $H_2O_2$  and  $O_2^{-}$  in the extracellular fluid \* Unit of Respiratory Medicine, Dept of Medicine (RIE), Rayne Laboratory, City Hospital, \*\* Institute of Occupational Medicine, and \*\*\* Dept of Biochemistry, University of Edinburgh, Scotland, UK.

Correspondence: Dr W. MacNee, Unit of Respiratory Medicine, City Hospital, Greenbank Drive, Edinburgh EH10 5SB, UK.

Keywords: Alveolar macrophage; glutathione; N-acetylcysteine; neutrophil; oxygen radicals.

Received: February 1, 1990; accepted after revision January 2, 1991.

This study was supported by Zambon Pharmaceuticals, Italy.

limits the generation of the highly reactive hydroxyl radical (OH), produced by the Fenton reaction, and hypochlorous acid (HOCl), mediated by myeloperoxidase in the presence of halide [10].

Previous work has demonstrated the effectiveness of N-acetylcysteine (NAC) as an antioxidant in vitro [11-14]. However, in vivo, NAC needs to be present in high concentrations in extracellular fluid to scavenge oxygen radicals. Adequate concentrations of NAC may be difficult to achieve in plasma, since the bioavailability of the drug, following oral dosing, is reported to be less than 5% [12]. However, NAC has been observed to attenuate the injurious effects of endotoxin in the lungs of sheep [14] and to normalize cigarette smoke induced dysfunction in macrophages [2, 15, 16], lung fibroblasts and epithelial cells [12], in both rats and humans. Further in vitro work has suggested that NAC can prevent the inactivation of alpha,-proteinase inhibitor  $(\alpha, -PI)$  by scavenging the neutrophil myeloperoxidase derived oxidant, hypochlorous acid (HOCl) [17, 18]. NAC is rapidly de-acetylated to cysteine during its first pass through the liver. Moreover, cysteine is a precursor in the biosynthesis of glutathione, itself and antioxidant [13, 15].

The aims of this study were to measure the effect of NAC, given by mouth, on NAC, cysteine and glutathione levels in human plasma and neutrophils, and in bronchoalveolar lavage fluids and alveolar macrophages from rats. Secondly, we wished to determine if the administration of NAC affected the subsequent generation of  $H_2O_2$  and  $O_2^-$  from rat leucocytes.

#### Subjects and methods

N-acetylcysteine in the form of a water soluble powder containing 200 mg NAC per sachet was provided by Zambon Pharmaceuticals, Milan, Italy.

#### Rat bronchoalveolar lavage studies

Syngeneic specific pathogen free (SPF) rats (200 g) of the PVG strain were given NAC in their drinking water such that they ingested 10 mg·kg<sup>-1</sup>·day<sup>-1</sup> (twice the human dose). After treatment for 5 days the rats were killed, their lungs removed and lavaged with 4×8 ml aliquots of saline as described previously [19]. The resulting bronchoalveolar lavage fluid was spun at 1,600 rpm, at 4°C for 10 min. Bronchoalveolar leucocytes (97% alveolar macrophages and 3% lymphocytes) were resuspended in phosphate buffered saline (PBS) to a concentration of 1×10<sup>7</sup> cells·ml<sup>-1</sup>. Comparisons were made with alveolar macrophages from PVG rats which were not given NAC in their drinking water.

#### Human neutrophil studies

Eleven normal, nonsmoking volunteers (aged 24-37 yrs) were given 600 mg of NAC by mouth for 5 days. Thirty ml of citrated venous blood were withdrawn from each subject on Day 1, prior to the first dose of NAC, and on Day 5, one and a half hours after the final dose. The samples of whole blood were mixed with Dextran (MW 70,000) (Travenol, UK) and allowed to sediment for one hour. The resulting leucocyte-rich plasma was overlaid on a Plasma/Percoll density gradient (Pharmacia, Sweden) and centrifuged to obtain a leucocyte band which was washed and lysed to remove contaminating erythrocytes, using a technique described previously [1]. The remaining neutrophil population (>95% pure) was resuspended in PBS at a concentration of 1×10<sup>7</sup>cells·ml<sup>-1</sup>. The viability of neutrophils harvested using this technique was >98% by trypan blue exclusion.

#### Hydrogen peroxide assay

 $H_2O_2$  generation was measured by the method of PICK and KEISARI [20]. The reaction mixture consisted of 100 ml 10 mM potassium phosphate buffer (10 mM KH<sub>2</sub>PO<sub>4</sub>, 7.6 mM K<sub>2</sub>HPO<sub>4</sub>), containing 1 ml of stock Type II, salt-free horseradish peroxidase 5 mg·ml<sup>-1</sup> in 0.05 M potassium phosphate buffer; 1 ml of 0.028 M phenol red; 140 mM sodium chloride and 5.5 mM dextrose (Sigma, UK). Alveolar macrophages or neutrophils ( $2.5 \times 10^5$  cells) were added to 1 ml of the reaction mixture. Both the spontaneous and phorbol myristate acetate (PMA, 1 µg·ml<sup>-1</sup>) (Sigma, UK) stimulated release of H<sub>2</sub>O<sub>2</sub> were measured after 2 h of incubation at 37°C, in 5% CO<sub>2</sub>. The reaction was terminated by centrifugation at 2,000 rpm, at 4°C for 10 min and the colour reaction was completed by alkalization with 1 M NaOH. The absorbance of the supernatant fluid was measured on a Pye Unicam SP8-400 spectro photometer at 610 nm and compared with a standard curve derived from dilutions of a reference solution of H<sub>2</sub>O<sub>2</sub>.

#### Superoxide anion assay

O, generation was measured by the superoxide dismutase (SOD)-inhibitable reduction of cytochrome c [21]. Inclusion of the enzyme SOD eliminates all cytochrome c reduction by agents other than  $O_2^-$ . The reaction mixture contained 80 M cytochrome c and 0.65 mM dextrose (Sigma, UK) in 50 ml of PBS. Tubes containing 1 ml of the reaction mixture and 2.5×105 alveolar macrophages or neutrophils were set up with identical tubes which, in addition, contained 75,000 units SOD (Sigma, UK). Release of  $O_2^-$  either spontaneously, or when stimulated with PMA 1 µg·ml<sup>-1</sup>, was measured after incubation for 2 h at 37°C in 5% CO2. O, generation is linear for up to 2 h incubation [21-23]. The reactions were terminated by centrifugation at 2,000 rpm, at 4°C for 10 min. The difference in absorbance of the supernatant fluids, in the presence or absence of SOD, was determined in a Pye Unicam SP8-400 spectrophotometer at 550 nm, and the amount of reduced ferricytochrome c was calculated based on an extinction coefficient of 21.0 mM<sup>-1</sup>·cm<sup>-1</sup> for cytochrome c.

### NAC, cysteine and glutathione assays

NAC, cysteine and reduced glutathione concentrations were determined by derivatization with monobromobimane (Thiolyte, Calbiochem) to form fluorescent adducts, which were then separated and quantified using reverse phase high performance liquid chromatography [24, 25].

#### Catalase assay

Catalase activity was determined using a spectrophotometer assay with titanium sulphate [25].

## Statistical analysis

Statistical analyses were performed on the mean values and standard deviations using the Student's t-test for paired samples.

## Results

Reduced or free thiol levels measured in human plasma or neutrophils, and rat bronchoalveolar lavage fluid (BALF) or alveolar macrophages are shown in tables 1 and 2. In normal subjects following treatment with NAC, plasma cysteine increased significantly (p<0.01) with a trend for plasma GSH to increase, occurring in 5 of the 8 subjects studied. However, neither the level of intracellular cysteine nor free glutathione (GSH) in neutrophils changed significantly. In the rat, cysteine levels increased in BALF without significant change in the GSH levels after treatment with NAC (table 1). NAC was not detectable in human plasma and neutrophils nor in rat macrophages and BALF (data not shown).

In separate experiments, intracellular cysteine and GSH in rat macrophages did not alter following treatment with NAC. However, catalase activity measured in rat macrophages was observed to increase following NAC (control 63.6±16.3, NAC 84.0±13.8 U·mg<sup>-1</sup> protein; n=6: p<0.05), but was not detectable in the extracellular fluid. In these experiments NAC produced a significant increase in BALF GSH but no change in cysteine levels (table 2).

The spontaneous or stimulated generation of H,O, by rat alveolar macrophages did not change following treatment with NAC (spontaneous release H2O2: control 6.36±2.4, NAC 6.9±2.8 mM·2.5×10.5 cells; stimulated release H<sub>2</sub>O<sub>2</sub>: control 15.3±3.8, NAC 14.4±4.2 nM·2.5×10<sup>-3</sup> cells; n=9, p>0.05) (fig. 1A).

8

0

00

ଞ

Α

21

18

15

12

9

6

3

0

H<sub>2</sub>O<sub>2</sub> release nmols·2.5×10<sup>-5</sup> AM




Table 1. - Cysteine (CYSH) and glutathione (GSH) levels in human plasma and neutrophils (PMNL) and rat bronchoalveolar lavage (BAL) before and after N-acetylcysteine (NAC)

|  |        |        | CYSH                      |             |                   | GSH                 |                    |  |
|--|--------|--------|---------------------------|-------------|-------------------|---------------------|--------------------|--|
|  |        |        | Co                        | ntrol       | NAC<br>5 days     | Contro              | l NAC<br>5 days    |  |
| Norm   | al sul | bjects |                           |             |                   |                     |                    |  |
| Plasma<br>nM·ml⁻¹                                    |        |        | 6.7                       | ±1.9<br>(n= | 9.8±3.5**<br>:11) | 2.9±1.              | 1 4.3±2.4<br>(n=8) |  |
| PMNL<br>nM·10 <sup>-6</sup> cells                    |        | lls    | 0.1±0.1 0.1±0.0<br>(n=11) |             | 1.7±0.            | 6 1.9±0.4<br>(n=10) |                    |  |
| PVG rats<br>BAL<br>nM·ml <sup>-1</sup>               |        |        | 0.7±0.6 1.1±0.9*<br>(n=9) |             | 2.7±2.            | 7 2.5±1.4<br>(n=9)  |                    |  |
| **p<0  |        | *p<0.0 | 5.                        |             |                   |                     |                    |  |
|  | 12     | В      |                           |             |                   |                     |                    |  |
|  |        |        |                           |             |                   | 0                   |                    |  |
| MM   |        |        |                           |             |                   | 000 B               | <u>نه</u> ک        |  |
| 02 <sup></sup> release nmols·2.5×10 <sup>-5</sup> AM | 9      |        |                           |             |                   | 0                   |                    |  |
|  |        |        |                           |             |                   | 0                   |                    |  |
| mols.  | 6      |        |                           |             |                   |                     |                    |  |
| ase n  |        |        |                           |             |                   |                     |                    |  |
| - relea  |        |        |                           |             |                   |                     |                    |  |
| 02.  | 3      |        | • ••                      |             |                   |                     |                    |  |
|  |        |        |                           | 0           | Ō                 |                     |                    |  |
|  |        | ≏      |                           |             |                   |                     |                    |  |
|  |        |        |                           |             |                   |                     |                    |  |

Spontaneous PMA 1 µg·ml-1

Spontaneous PMA 1 µg·mi

Fig. 1. - (A) Hydrogen peroxide (H2O2) and (B) superoxide anion (O2-) production by alveolar macrophages obtained from 9 rats after 5 days' treatment with N-acetylcysteine (NAC) (1), and 9 control animals not given NAC (O). Both spontaneous levels and those on stimulation with phorbol-myristate-acetate (PMA) and the mean values (A) are shown. The bars represent the standard errors of the mean. (\*\*\*: p<0.001).

Table 2. – Cysteine (CYSH) and glutathione (GSH) levels in rat bronchoalveolar lavage (BAL) and alveolar macrophages (AM) before and after N-acetylcysteine (NAC)

|                           | CY      | SH            | GSH     |               |  |
|---------------------------|---------|---------------|---------|---------------|--|
|                           | Control | NAC<br>5 days | Control | NAC<br>5 days |  |
| PVG Rats                  | 0.3±0.2 | 0.3±0.1       | 3.2±0.9 | 4.5±1.1*      |  |
| BAL nM·ml·1               | (n=     | =6)           | (n=     | =6)           |  |
| AM                        | 0.7±0.2 | 0.6±0.1       | 3.4±0.8 | 3.2±0.9       |  |
| nM·10 <sup>-6</sup> cells | (n=     | =6)           | (n=     | =6)           |  |

\*p<0.05.

statistical significance (stimulated release  $H_2O_2$ : control 27.1±10.0 NAC 45.7±27.1 nM·2.5×10<sup>-5</sup> cells; n=11, p>0.05).

The spontaneous generation of  $O_2^-$  from human neutrophils tended to increase following NAC but this change was not significant (spontaneous release  $O_2^-$ : control 1.5±0.4, NAC 2.2±1.4 nM·2.5×10<sup>-5</sup> cells; n=11, p>0.05). The PMA stimulated release of  $O_2^-$  by contrast tended to fall following treatment with NAC, but again this change was not significant (stimulated release  $O_2^-$ : control 18.6±1.6, NAC 9.9±5.2 nM·2.5×10<sup>-5</sup> cells; n=11, p>0.05) (fig. 2B).




Fig. 2. – (A) Hydrogen peroxide  $(H_2O_2)$  and (B) superoxide anion  $(O_2^{-})$  production by human neutrophils from 11 normal subjects before (O) and after ( $\odot$ ) 5 days' treatment with N-acetylcysteine (NAC). Both the spontaneous levels and those on stimulation with phorbolmyristate-acetate (PMA) and the mean values ( $\blacktriangle$ ) are shown. The bars represent the standard errors of the mean. \*\*: p<0.02.

Human neutrophils from 11 normal subjects treated with NAC for 5 days showed a small but significant increase in the spontaneous release of  $H_2O_2$  compared with pretreatment values (spontaneous release  $H_2O_2$ : control 2.5±1.3, NAC 6.4±4.3 nM·2.5×10<sup>-5</sup> cells; n=11, p<0.02) (fig. 2A). Although neutrophils from 7 of the 11 subjects showed an increase in the PMA stimulated generation of  $H_2O_2$ , this trend did not achieve

## Discussion

This study failed to show any significant decrease in the release of  $H_2O_2$  or  $O_2^-$  from human peripheral blood neutrophils and rat alveolar macrophages. On the contrary, small increases in the spontaneous release of  $O_2^-$  from rat macrophages and  $H_2O_2$  from human neutrophils was demonstrated.

The thiol compound N-acetylcysteine (NAC) is known to scavenge free electrolytes such as hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), and reactive oxygen species such as superoxide anion (O<sub>2</sub>-). In vitro studies have previously demonstrated a reduction in the chemiluminescence of stimulated human neutrophils following incubation with NAC [11]. Similarly BERNARD et al. [14], employed the chemiluminescence assay to demonstrate the reduced ability of zymosan or PMA stimulated sheep neutrophils to scavenge oxygen metabolites when incubated with NAC. However, the bioavailability of NAC is only 5%, because of its extensive first pass metabolism by the liver [12]. Indeed NAC was not detectable in plasma or BALF in this study, or in our previous study [26]. Thus, it is unlikely that concentrations of NAC in body fluids are high enough to achieve such a scavenging action.

Nevertheless, recent in vivo work has shown that NAC protects against smoke induced cellular damage to both the rat [12] and human lung [2, 12, 18], possibly by enhancing cysteine levels and thus GSH biosynthesis [13]. Further in vivo studies, such as that by BERGSTRAND et al. [15] have also demonstrated a reduction in  $O_2^-$  generation by smokers' macrophages after treatment with NAC for 8 weeks. Similarly, treatment with NAC was observed to reduce the chemiluminescence of zymosan stimulated human neutrophils [27]. Furthermore, DE FLORA et al. [28] observed increased hexose monophosphate shunt (HMPS) activity in rat macrophage following NAC, and KHARAZMI et al. [11] observed an increased oxygen consumption, also suggesting increased HMPS activity, in the face of a reduction in chemiluminescence in neutrophils treated with NAC. The authors of these studies suggest that the increased activity of the HMPS following NAC may be explained by an increase in H<sub>2</sub>O<sub>2</sub> catabolism by the glutathione system.

The aim of this study was to determine if NAC given in vivo resulted in increased glutathione biosynthesis, thereby preventing free radical generation as suggested in recent reports [29, 30]. However, in this study we have employed specific assays to detect nanomole amounts of  $H_2O_2$  and  $O_2^-$ , whereas many of the previously published studies which have investigated the role of NAC as an antioxidant have used the less specific chemiluminescence assay [11, 14, 27].

Our results from human studies indicate that although there was a small increase in plasma cysteine, intracellular thiol levels were not significantly altered by NAC. Although MOLDEUS *et al.* [12] have shown a significant increase in plasma GSH in healthy volunteers following NAC 200 mg twice daily for two weeks, we have previously shown that following 5 days' treatment with a single dose of NAC the GSH levels peak at variable intervals between 2 and 8 h [26]. Plasma cysteine levels, however, peak 90 min after the last dose of NAC [26]. The fact that we sampled blood 90 min after the last dose of NAC may therefore explain the significant increase in plasma cysteine but not plasma GSH levels. It is also possible that any increase in GSH may have been lost as a result of the two hour period required to harvest a pure population of neutrophils. However, intracellular thiol levels which did not increase following NAC, are likely to be more stable than plasma and BALF levels (M. Bridgemen, unpublished observations). We assayed total *i.e.* both oxidised and reduced cysteine and GSH levels, in some of the human subjects (data not shown). These were only marginally higher than the reduced values alone, which is in agreement with other workers [31] and suggests that most of the thiols were present in the free, reduced form.

There was no significant reduction in the release of H2O2 or O2 from neutrophils following treatment with NAC. Indeed, the spontaneous production of H<sub>2</sub>O<sub>2</sub> was significantly increased after NAC. A similar trend for the PMA stimulated release of H<sub>2</sub>O<sub>2</sub> and the spontaneous release of O2 to increase was also observed. An increase in the spontaneous release of H<sub>2</sub>O<sub>2</sub> from neutrophils, following NAC without a significant reciprocal change in O2 production, as observed in this study may simply be explained by the individual results in figure 2 which show a similar trend for spontaneous O2- to increase following NAC as with  $H_2O_2$ . However, the molar ratios observed in this study also suggest that significantly more H<sub>2</sub>O<sub>2</sub> than O<sub>2</sub> was generated from stimulated human neutrophils following treatment with NAC. This appears stoichometrically erroneous since the reduction of molecular oxygen:

$$\begin{array}{c} O_2^{-+}2e \rightarrow 2O_2 \\ 2O_2^{+}2H^+ \rightarrow H_2O_2^{+}O_2^{--} \end{array}$$

predicts a molar ratio of 2:1 for O2-/H2O2 production. This apparently contradictory result could be explained by the release of  $O_2^-$  from the cell membrane into phagosomes which would prevent its detection in our assay by the scavenger cytochrome c. Furthermore, within the phagosome the O,- would have more time, both spontaneously and in the presence of SOD, to dismutate to H,O, before its secretion/diffusion out of the cell [32]. This mechanism may also explain the decrease observed in the stimulated release of O2- from human neutrophils following NAC occurring in 8 of the 11 subjects studied (fig. 2B). In addition, any catabolism of H2O2 by myeloperoxidase in the phagosome, or by catalase or the glutathione system in the cytosol could also reduce the levels of H,O, which were detected. Indeed, plasma myeloperoxidase was observed by EKLUND et al. [33] to fall following treatment over 8 weeks with NAC. Yet, despite the possible catabolism of H<sub>2</sub>O<sub>2</sub> by myeloperoxidase, an increased H<sub>2</sub>O<sub>2</sub> production was evident in most individuals following NAC in this study. Reduced chemiluminescence observed by many workers following treatment with NAC [11, 14, 27] may reflect a reduction in myeloperoxidase activity as a result of myeloperoxidase entrapment in phagosomes and/or its catabolism of H2O2, as the chemiluminescence assay is both myeloperoxidase and O,- dependent [23]. Intracellular thiol levels in human neutrophils, however, did not increase following NAC.

In the animal study, our results indicate a small increase in the spontaneous O<sub>2</sub><sup>-</sup> production from rat alveolar macrophage following treatment with NAC. The animals did ingest NAC, as shown by the significant increase in BAL cysteine, although the changes were small (table 1) and were not sufficient to have a significant effect since intracellular thiols did not alter (table 2). Recent human studies have demonstrated that thiol levels in BAL fluid increase in a dose-dependent fashion [26]. However, in separate experiments in rats, we showed a significant increase in intracellular catalase activity in alveolar macrophages but not in BAL, which may also explain the lack of any increase in spontaneous H<sub>2</sub>O<sub>2</sub> generation from alveolar macrophages in spite of a small, but significant, increase in spontaneous O<sub>2</sub><sup>-</sup> release following NAC. Interference of the O<sub>2</sub><sup>-</sup> assay by catalase is unlikely as cytochrome c reduction is not affected by catalase. In this case, in contrast to the data in table 1, GSH but not cysteine levels increased in BALF (table 2). This apparent contradictory result, we believe, may result from a later sampling time of BALF following NAC ingestion in these experiments since our previous work suggests that cysteine peaks earlier than GSH in BALF in man following ingestion of NAC [26]. However, because of the difficulty in accurately determining the time from last dosage of NAC to the time when lavage was carried out in the rat, this hypothesis remains unproven.

In summary, although N-acetylcysteine may act as an antioxidant in vitro as a precursor of cysteine and thus glutathione biosynthesis, we found no evidence to suggest that administration of NAC resulted in reduced H<sub>2</sub>O<sub>2</sub> and O<sub>2</sub><sup>-</sup> generation from lung phagocytes. Indeed, NAC significantly increased the spontaneous oxygen radical production from these cells. This increase in oxygen radical release was small and, therefore, is unlikely to have any clinical significance. An increase in plasma cysteine, however, in the absence of free iron, may scavenge free radicals released into the micro-environment surrounding phagocytic cells, and may help to explain the effect of NAC in protecting the lungs against injury induced by inhaled oxidants such as cigarette smoke, or released from activated phagocytes during inflammation or infection.

> Acknowledgements: The authors wish to thank C. Hendrie for secretarial assistance, and M. Marsden for technical assistance.

#### References

1. MacNee W, Wiggs B, Belzberg AS, Hogg JC. – The effect of cigarette smoking on neutrophil kinetics in the lungs. *N Engl J Med*, 1989, 321 (14), 924–928.

2. Linden M, Wieslander E, Eklund A, Larsson K, Brattsand R. – Effect of oral N-Acetylcysteine on cell content and macrophage function in bronchoalveolar lavage from healthy smokers. *Eur Respir J*, 1988, 1, 645–650.

3. Janoff A, Pryor WA, Bengali ZH. – NHLBI Workshop Summary: Effects of tobacco smoke components on cellular and biochemical processes in the lung. Am Rev Respir Dis, 1987, 136, 1058-1064.

4. Currie DC, Needham S, Peters AM, Cole PJ, Lavender JP. – <sup>111</sup>Indium labelled neutrophils migrate to the lungs in bronchiectasis. *Lancet*, 1987, i, 1335–1339.

5. Hunninghake GW, Gadek JE, Kawanami O, Ferrans VJ, Crystal RG. – Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. Am J Pathol, 1979, 97, 149–206.

Kharazmi A, Schiotz PO, Hoiby N, Baek L, Doring G.
Demonstration of neutrophil chemotactic activity in the sputum of cystic fibrosis patients with *Pseudomonas aeruginosa* infection. *Eur J Clin Invest*, 1986, 16, 143–148.
Fantone JC, Ward PA. – Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. *Am J Pathol*, 1982, 107 (3), 398–428.

8. Ward PA, Johnson KJ, Till GO. – Animal models of oxidant lung injury. *Respiration*, 1986, 50, 5–12.

9. Varani J, Fligiel SEG, Till GO, Klinkel RG, Ryan US, Ward PA. – Pulmonary endothelial cell killing by human neutrophils. Possible involvement of hydroxyl radical. *Lab Invest*, 1985, 53 (6), 656–663.

10. Henson PM, Johnston RB. – Tissue injury in inflammation: oxidants, proteinases and cationic proteins. J Clin Invest, 1987, 79, 669-674.

11. Kharazmi A, Nielsen H, Schiotz PO. – N-Acetylcysteine inhibits human neutrophil and monocyte chemotaxis and oxidative metabolism. Int J Immunopharmac, 1988, 10 (1), 39-46.

12. Moldeus P, Cotgreave IA, Berggren M. – Lung protection by a thiol-containing antioxidant: N-Acetylcysteine. *Respiration*, 1986, 50 (1), 31-42.

13. Meister A, Andersson M. – Glutathione. Ann Rev Biochem, 1983, 52, 711–760.

14. Bernard GR, Lucht WD, Niedermeyer ME, Snapper JR, Ogletree ML, Brigham KL. – Effect of N-Acetylcysteine on the pulmonary response to endotoxin in the awake sheep and upon *in vitro* granulocyte function. J Clin Invest, 1984, 73, 1772–1784.

15. Bergstrand H, Bjornson A, Eklund A, Hernbrand R, Larrson K, Linden M, Nilsson A. – Stimuli-induced superoxide radical generation *in vitro* by human alveolar macrophages from smokers: modulation by N-Acetyl cysteine treatment *in vivo. J Free Rad Biol Med*, 1986, 2, 119–127. 16. Voisin C, Aerts C, Wallaert B. – Prevention of *in vitro* oxidant mediated alveolar macrophage injury by cellular glutathione and precursors. *Bull Eur Physiopathol Respir*, 1987, 23(4), 309–313.OL6.

17. Aruoma OI, Halliwell B, Hoey BM, Butler J. – The antioxidant action of N-acetyl cysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide and hypochlorous acid. J Free Rad Biol Med, 1989, 6, 593–597.

18. Borregaard N, Jensen HS, Bjerrum OW. – Prevention of tissue damage: inhibition of myeloperoxidase mediated inactivation of proteinase inhibitor by N-acetyl cysteine, glutathione and methionine. Agents Actions, 1987, 22 (3), 255–260.

19. Donaldson K, Slight J, Bolton RE. – Oxidant production by control and inflammatory bronchoalveolar leukocyte populations treated with miner dust *in vitro*. Inflammation, 1988, 12(3), 231–243.

20. Pick E, Keisari Y. – A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture. J Immunol Methods, 1980, 38, 161–170.

21. Donaldson K, Slight J, Brown GM, Bolton RE, Davies JMG. – The role of macrophages as a source of reactive

oxygen intermediates in pulmonary inflammation associated with pathogenic dusts. Inst of Occup Med Tech Mem, 1986, 09.

22. Johnston RB Jr. – Secretion of superoxide anion. Methods for studying mononuclear phagocytes. Academic Press, 1981, 52, 489.

23. Rosen M, Klebanoff SJ. – Chemiluminescence and superoxide production by myeloperoxidase-deficient leukocytes. J Clin Invest, 1976, 58, 50-60.

24. Cotgreave IA, Moldeus P. – Simple methodologies for the determination of reduced and oxidised low molecular weight and protein thiol components of biological systems using monobromobiomone. J Biochem Biophys Meth, 1986, 13, 231–249.

25. Leighton F, Poole B, Beaufay H, Baudhuim P, Coffey JN, Fowler S, De Cuve C. – The large scale separation of peroxisomes, mitochondria and lysosomes from the livers of rats injected with Triton WR-1339. J Cell Biol, 1968, 37, 482–513.

26. Bridgeman M, Marsden M, MacNee W, Flenley DC, Ryle AP. – Changes in cysteine and reduced glutathione following treatment with N-Acetyl cysteine. *Thorax*, 1991, 46, 39–42.

27. Jensen T, Kharazmi A, Schiotz PO, Nielsen H, Pedersen SS, Stafanger G, Koch C, Hoiby N. – Effect of oral N-Acetylcysteine administration on human blood neutrophil and monocyte function. *APMIS*, 1988, 96, 62–67.

28. De Flora S, Romano M, Basso C, Bagnasco M, Cesarone CF, Rossi GA, Morelli A. – Detoxifying activities in alveolar macrophages of rats treated with acetylcysteine, diethyl maleate, and/or aroclor. *Anticancer Res*, 1986, 6(5), 1009–1012.

29. Simon LM, Suttorp N. – Lung cell oxidant injury: decrease in oxidant mediated cytotoxicity by N-Acetyl cysteine. *Eur J Respir Dis*, 1985, 66, 132–135.

30. Wagner PD, Mathieu-Costello O, Bebout DE, Gray AT, Natterson PD, Glennow C. – Protection against pulmonary O<sub>2</sub> toxicity by N-acetylcysteine. *Eur Respir J*, 1989, 2, 116–126.

31. Voetman AA, Loos JA, Roos D. – Changes in the level of glutathione and other sulphydryl compounds in human polymorphonuclear leukocytes at rest and during phagocytosis. *Blood*, 1980, 55, 741–747.

32. Root RK, Metcalf JA.  $- H_2O_2$  release from human granulocytes during phagocytosis: relationship to superoxide

anion formation and cellular catabolism of  $H_2O_2$ : studies with normal and cytochalasin B-treated cells. J Clin Invest, 1977, 60, 1266–1279.

33. Eklund A, Eriksson O, Hakansson L, Larson K, Ohlsson K, Venge P, Bergstrand H, Bjornson A, Brattsand R, Glennow C, Linden M, Wieslander E. – Oral N-Acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables. *Eur Respir J*, 1988, 1, 832–838.

Absence d'effet de la N-acétyl cystéine sur la libération de radicaux d'oxygène à partir des neutrophiles et des macrophages alvéolaires. E. Drost, S. Lannan, M.M.E. Bridgeman, D. Brown, C. Selby, K. Donaldson, W. MacNee. RÉSUMÉ: La N-acétyl cystéine (NAC) est rapidement désacétylée in vivo en cystéine (CYSH), un précurseur du glutathion (GSH) qui est un anti-oxydant dans les cellules et les liquides organiques.

Nous avons investigué les effets de l'administration orale de N-acétyl cystéine pendant 5 jours sur la production spontanée et stimulée de peroxyde d'hydrogène  $(H_2O_2)$  et d'anion superoxyde  $(O_2^{-})$  par les leucocytes phagocytaires de l'homme et du rat. Des macrophages alvéolaires ont été obtenus par lavage broncho-alvéolaire chez les rats contrôle et les rats auxquels NAC avait été administrée dans leur eau de boisson. Les neutrophiles (PMNL) ont été prélevés dans le sang complet chez des volontaires normaux non fumeurs, avant et après administration de NAC par la bouche.

La libération stimulée de  $H_2O_2$  et de  $O_2^-$  à partir des macrophages alvéolaires du rat et des polymorphonucléaires humains n'est pas modifiée par l'administration de NAC. Toutefois, une augmentation modeste mais significative a été observée dans la production spontanée de  $O_2^-$  par les macrophages alvéolaires du rat et la production spontanée de  $H_2O_2$  par les polymorphonucléaires humains. L'administration de N-acétyl cystéine augmente significativement les niveux de cystéine dans le plasma humain et dans le BAL du rat, mais les niveaux observés dans les PMNL humains et les AM du rat après NAC ne sont pas différents de ceux des contrôles. Les niveaux de GSH n'ont pas été affectés significativement par la NAC.

Eur Respir J, 1991, 4, 723-729.